HIF1α and HIF2α independently activate SRC to promote melanoma metastases

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 2078-2093

  Hanna, Sara C ^a   Krishnan, Bhavani ^a   Bailey, Sean T ^a   Moschos, Stergios J ^a   Kuan, Pei Fen ^a,b   Shimamura, Takeshi ^c   Osborne, Lukas D ^d   Siegel, Marni B ^a   Duncan, Lyn M ^e   O'Brien III, E Tim ^d   Superfine, Richard ^d   Miller, C Ryan ^a,f   Simon, M Celeste ^g   Wong, Kwok Kin ^h,i   Kim, William Y ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MATRIX METALLOPROTEINASE; MELATONIN 1 RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL MOTILITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; MELANOMA METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SRC HOMOLOGY DOMAIN; TUMOR CELL; TUMOR INVASION;

ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; EXTRACELLULAR MATRIX; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA; MICE; MICROSCOPY, FLUORESCENCE; MUTATION; NEOPLASM METASTASIS; ONCOGENES; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; SKIN NEOPLASMS;

EID: 84877101126     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66715     Document Type: Article

References (41)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012;12(5):349-361.
3. Kaelin WG, Ratcliffe PJ. Oxygen sensing by meta-zoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402.
4. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991-5004.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732.
6. Kim WY, et al. Failure to prolyl hydroxylate hypox-ia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J. 2006;25(19):4650-4662.
7. Raval RR, et al. Contrasting properties of hypoxiainducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25(13):5675-5686.
8. Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003;23(24):9361-9374.
9. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12(1):9-22.
10. Adelman DM, Gertsenstein M, Nagy A, Simon MC, Maltepe E. Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev. 2000;14(24):3191-3203.
11. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist. 2008;13(suppl 3):21-26.
12. Kozak KR, Abbott B, Hankinson O. ARNT-deficient mice and placental differentiation. Dev Biol. 1997;191(2):297-305.
13. Cowden Dahl KD, Robertson SE, Weaver VM, Simon MC. Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell. 2005;16(4):1901-1912.
14. Giatromanolaki A, et al. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 2003;13(5):493-501.
15. Bedogni B, et al. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell. 2005;8(6):443-454.
16. Kumar SM, et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res. 2007;67(7):3177-3184.
17. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res. 2001;61(19):7349-7355.
18. Sodhi A, Montaner S, Miyazaki H, Gutkind JS. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem Biophys Res Commun. 2001;287(1):292-300.
19. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38-47.
20. Buscà R, et al. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol. 2005;170(1):49-59.
21. Feige E, et al. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci U S A. 2011; 108(43):E924-E233.
22. Cheli Y, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene. 2011;31(19):2461-2470.
23. Dankort D, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41(5):544-552.
24. Kim WY, et al. HIF2α cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 2009;119(8):2160-2170.
25. Murphy DA, Courtneidge SA. The 'ins' and "outs" of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 2011;12(7):413-426.
26. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6):470-480.
27. Eckert MA, et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011;19(3):372-386.
28. Yang M-H, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008;10(3):295-305.
29. Gort EH, et al. The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene. 2008;27(11):1501-1510.
30. Hu C-J, Sataur A, Wang L, Chen H, Simon MC. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell. 2007; 18(11):4528-4542.
31. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1(3):237-246.
32. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009;9(2):108-122.
33. Swaminathan V, et al. Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res. 2011;71(15):5075- 5080.
34. Cross SE, Jin Y-S, Rao J, Gimzewski JK. Nanomechanical analysis of cells from cancer patients. Nat Nanotechnol. 2007;2(12):780-783.
35. Spero RC, et al. High throughput system for magnetic manipulation of cells, polymers, and biomaterials. Rev Sci Instrum. 2008;79(8):083707.
36. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
37. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
38. Kondo K, Kim WY, Lechpammer M, Kaelin WG. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003; 1(3):E83.
39. Rankin EB, et al. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol. 2005;25(8):3163-3172.
40. Bertolotto C, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480(7375):94-98.
41. Nazarian RM, Prieto VG, Elder DE, Duncan LM. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol. 2010;37:41-47.